Active Ingredient: Tocilizumab
Tocilizumab is indicated for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 8 milligrams tocilizumab per kilogram of body weight, 1 to 2 doses in total.
The recommended posology for treatment of COVID-19 is a single 60-minute intravenous infusion of 8 mg/kg body weight in patients who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. If clinical signs or symptoms worsen or do not improve after the first dose, one additional infusion of tocilizumab 8 mg/kg may be administered. The interval between the two infusions must be at least 8 hours.
For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.
Administration of tocilizumab is not recommended in patients with COVID-19 who have any of the following laboratory abnormalities:
| Laboratory test type | Laboratory value | Action |
|---|---|---|
| Liver enzyme | > 10 × ULN | Administration of tocilizumab is not recommended |
| Absolute neutrophil count | < 1 × 109/L | |
| Platelet count | < 50 × 103/μL |
The recommended posology for treatment of CRS given as a 60-minute intravenous infusion is 8 mg/kg in patients weighing greater than or equal to 30 kg or 12 mg/kg in patients weighing less than 30 kg. Tocilizumab can be given alone or in combination with corticosteroids.
If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses must be at least 8 hours. Doses exceeding 800 mg per infusion are not recommended in CRS patients.
Patients with severe or life-threatening CRS frequently have cytopenias or elevated ALT or AST due to the underlying malignancy, preceding lymphodepleting chemotherapy or the CRS.
Intravenous infusion over 1 hour. If signs and symptoms of an infusion-related reaction occur, the infusion needs to be slowed or stopped and appropriate medicinal product/supportive care must be administered immediately.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.